Routine

Metabolic dysfunction-associated steatotic liver disease (MASLD / MASH / NAFLD)

MASLD, MASH, NAFLD, NASH, fatty liver, steatohepatitis, resmetirom · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hepatic steatosis (>5% of hepatocytes) with at least one cardiometabolic risk factor and no other cause. Spectrum: simple steatosis -> metabolic dysfunction-associated steatohepatitis (MASH, with inflammation/ballooning) -> fibrosis -> cirrhosis and HCC. Now the commonest chronic liver disease. Management targets metabolic drivers and fibrosis risk stratification.

Red flags

  • Features of cirrhosis/portal hypertension (low platelets, splenomegaly, ascites, varices)
  • High FIB-4 / high liver stiffness (advanced fibrosis)
  • Rapidly rising transaminases or bilirubin (reconsider diagnosis)
  • New liver mass / rising AFP (HCC)
  • Decompensation: jaundice, ascites, encephalopathy, variceal bleed

Assessment

Differential diagnosis

  • Alcohol-associated liver disease (MetALD if both; quantify intake)
  • Chronic viral hepatitis (B/C)
  • Drug-induced steatosis (methotrexate, tamoxifen, amiodarone, steroids)
  • Autoimmune hepatitis
  • Haemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency
  • Coeliac disease, hypothyroidism, PCOS (associated)

Investigations

  • Confirm steatosis (USS/other imaging) and cardiometabolic risk factors (obesity, type 2 diabetes, hypertension, dyslipidaemia)
  • Exclude other causes: alcohol history, hepatitis B/C serology, autoimmune (ANA/SMA, immunoglobulins), ferritin/transferrin saturation, caeruloplasmin if young, alpha-1 antitrypsin, TFTs, coeliac
  • FIB-4 as first-line non-invasive fibrosis score (age, AST, ALT, platelets); low (<1.3) reassuring, >=1.3 (or >2.0 if >65) needs further assessment
  • Transient elastography (FibroScan) / ELF test as second-line fibrosis assessment; liver biopsy in selected uncertain/high-risk cases
  • Full metabolic work-up: HbA1c/fasting glucose, lipid profile, BP, BMI/waist; cardiovascular risk assessment
  • HCC/varices surveillance if advanced fibrosis/cirrhosis established

Management

  • Diagnose MASLD (steatosis + >=1 cardiometabolic criterion) and exclude alternative/co-existing liver disease
  • Risk-stratify fibrosis with FIB-4 -> FibroScan/ELF pathway; advanced fibrosis drives prognosis and referral
  • Lifestyle is foundation: aim >=7-10% weight loss (improves/resolves MASH and fibrosis); Mediterranean diet, reduce sugar/ultra-processed food, exercise, limit alcohol
  • Optimise metabolic comorbidities: treat type 2 diabetes (prefer agents with liver/weight benefit), hypertension, dyslipidaemia - statins are SAFE and indicated for cardiovascular risk
  • Consider GLP-1 receptor agonists (e.g. semaglutide) for weight/diabetes with liver benefit; pioglitazone or vitamin E in selected biopsy-proven MASH (non-diabetic) per specialist
  • Consider resmetirom for biopsy/imaging-confirmed MASH with F2-F3 fibrosis where available (specialist, with lifestyle)
  • Manage the dominant cause of mortality - CARDIOVASCULAR disease - aggressively; bariatric surgery for eligible patients
  • Surveillance for HCC and varices if advanced fibrosis/cirrhosis; refer hepatology if advanced fibrosis

Drugs & doses

Weight loss / lifestyle is first-line (target >=7-10% body weight) - no drug replaces this
Resmetirom (THR-beta agonist) PO once daily, weight-based (e.g. 80 mg if <100 kg, 100 mg if >=100 kg) for MASH with F2-F3 fibrosis, with diet/exercise - FDA accelerated approval 2024 [verify local availability/approval]
Semaglutide (GLP-1 RA) SC titrated - for coexisting type 2 diabetes/obesity; approved for MASH (2025) in some regions [verify local]
Pioglitazone 30-45 mg PO once daily in selected biopsy-proven MASH without diabetes (weight gain/fluid caution) [verify local]
Vitamin E 800 IU PO daily in selected non-diabetic biopsy-proven MASH (discuss risks) [verify local]
Statin (e.g. atorvastatin) for cardiovascular risk - safe in MASLD including compensated disease; do not withhold for mildly raised transaminases
Optimise antidiabetic/antihypertensive/lipid therapy per cardiovascular risk

Disposition

Outpatient / primary care with metabolic optimisation. Hepatology referral for advanced fibrosis/cirrhosis, diagnostic uncertainty, or MASH-specific pharmacotherapy. Admit only for decompensation/HCC.

Complications & pitfalls

  • Progression to cirrhosis and hepatic decompensation
  • Hepatocellular carcinoma (can occur, occasionally without cirrhosis)
  • Cardiovascular disease - the LEADING cause of death in MASLD
  • Type 2 diabetes, chronic kidney disease, extrahepatic cancers
  • Oesophageal varices / portal hypertension if advanced

Exam pearls

  • AASLD 2023 / EASL: use FIB-4 first-line to risk-stratify fibrosis, then FibroScan/ELF - fibrosis stage, not steatosis, predicts outcome.
  • Resmetirom (Rezdiffra) gained FDA accelerated approval in 2024 as the first drug for MASH with F2-F3 fibrosis, alongside lifestyle - biopsy not mandatory for eligibility. [verify local availability]
  • >=7-10% weight loss can resolve MASH and regress fibrosis - lifestyle remains the cornerstone; GLP-1 agonists help weight/diabetes.
  • Statins are SAFE and indicated in MASLD - cardiovascular disease, not liver disease, is the commonest cause of death; do not stop statins for mild transaminase rise.
  • The nomenclature changed from NAFLD/NASH to MASLD/MASH (2023); MetALD denotes coexisting significant alcohol use - always quantify alcohol intake.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.